Does evolocumab reduce mortality in adults with diabetes and no atherosclerosis?

Evolocumab & Mortality1 min readUpdated June 7, 2026

What the Evidence Shows

We analyzed two assertions about evolocumab in adults with diabetes who do not have advanced artery disease, and both support the idea that this medication is linked to a lower risk of death over five years. In one case, the risk of dying from any cause dropped from 10.1% to 7.8% with evolocumab...

Evidence from Studies

Supporting (0)
No supporting evidence found
Contradicting (0)
No contradicting evidence found
Primary Studies (1)

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

DOI: 10.1001/jama.2026.3277

Update History

Published
June 7, 2026·Last updated June 7, 2026
  • Invalid DateNew topic created from assertion
  • Invalid Datenew evidence added
  • Invalid DateNew topic created from assertion

Sign up to see full analysis